Searched for
EQUILLIUM
U.S. stock futures today in the red as Dow, S&P 500, Nasdaq fall ahead of pivotal inflation report — Tesla, AMD, Apple, Nvidia lead market moversU.S. stock futures were slightly in the red early Tuesday as Wall Street shifted into a holding pattern ahead of a highly anticipated Consu...- Biocon starts clinical study to evaluate efficacy of ItolizumabThis is a phase two randomised, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to eva...
- Biocon Biologics says clinical study for drug Itolizumab initiated in India after approval from DCGIBiocon's partner US-based Equillium Inc has expanded its 'EQUALISE' study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Ito...
- Biocon Q2 results: Net profit drops 22% on higher R&D cost; revenue jumps 10%Biocon reported a 10% rise in total revenue to Rs 1,760 crore driven by overall growth in generics, biosimilar and research services busine...
- Biocon extends licensing pact with Equillium for itolizumabItolizumab, a first-in-class humanized anti-CD6 monoclonal antibody, is developed by Biocon and launched in 2013 in India under the brand n...
- Biocon Q2 net profit at Rs 216 croreConsolidated total income of the company stood at Rs 1,610.6 crore for the quarter under consideration.
Load More